+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are studying the efficacy and safety of rilvegostomig combined with gemcitabine plus cisplatin compared to durvalumab combined with the same chemotherapy as first-line treatment for patients with advanced biliary tract cancer BTC. This Phase III, randomized, open-label study aims to evaluate these treatments in patients with unresectable locally advanced or metastatic BTC, including intra-hepatic or extra-hepatic cholangiocarcinoma and gallbladder carcinoma. Participants receive either rilvegostomig or durvalumab intravenously, both alongside gemcitabine and cisplatin chemotherapy. Durvalumab is given at 1500 mg IV every 3 weeks for up to 8 cycles, then every 4 weeks. Rilvegostomig is administered IV every 3 weeks. The chemotherapy regimen consists of gemcitabine 1000 mgm2 plus cisplatin 25 mgm2 on Day 1 and Day 8 of each 21-day cycle. Treatment continues according to the study protocol with close monitoring. During the study, participants undergo assessments including tumor measurements by CT or MRI using RECIST 1.1 criteria, evaluation of PD-L1 status, and performance status checks. Researchers also monitor overall survival and progression-free survival for up to approximately four years, as well as safety, tolerability, pharmacokinetics, and patient-reported symptoms and quality of life. Follow-up continues up to 12 weeks after disease progression for additional evaluations.

Age: 18Years +All GendersPhase 3
183 locations